关键词: PD-1/PDL-1, 肺癌, 衰弱, 影响因素

Abstract: Objective: To investigate the current status of frailty in lung cancer patients treated with PD-1/PDL-1 and analyze its influencing factors. Methods: A cross-sectional survey was conducted in 190 lung cancer patients who received PD-1/PDL-1 treatment at a tertiary Class A tumor specialized hospital in Tianjin using the general information questionnaire, Mini Nutrition Assessment Method Simplified Version, Barthel Index, Chinese version of Gliningen Weakness Index Scale, and Anderson Symptom Assessment Scale Revised Version. Results: Among the 190 patients, 57(30.0%) experienced weakness, while 23(12.1%) were in the early stages of weakness, and 110 (57.9%) did not experience weakness. Lasso regression results showed that Barthel index, nutrition score, sleep disorder, comorbidity, symptom score, fatigue, distress, forgetfulness, sadness, constipation and body mass decline were the influencing factors of frailty in lung cancer patients treated with PD-1/PDL-1. Conclusion: The incidence of frailty in lung cancer patients treated with PD-1/PDL-1 is at a moderate level. Patients with poor self-care ability, malnutrition, sleep disorder, patients with more than two comorbidities, and patients with high symptom scores should be paid more attention. Targeted intervention measures should be taken to respond actively, so as to alleviate the incidence of frailty in lung cancer patients treated with PD-1/PDL-1.

Key words: PD-1/PDL-1, Lung cancer, Frailty, Influence factor